About
OxSonics Therapeutics is a clinical-stage oncology company based in Oxford, United Kingdom. Founded in 2013 as a spinout from the University of Oxford’s Institute of Biomedical Engineering, the company specializes in an innovative ultrasound-based drug delivery platform known as SonoTran®. This technology addresses the challenge of poor drug penetration into solid tumors, which represent about 90% of adult cancers. The SonoTran Platform combines low-intensity focused ultrasound with injectable SonoTran Particles to enhance the delivery of unmodified cancer drugs directly into solid tumors. This method aims to improve the efficacy and reduce the toxicity of various anti-cancer agents, including antibodies and oncolytic viruses, without requiring drug reformulation. OxSonics collaborates with oncology drug developers and healthcare providers to enhance cancer therapy delivery, focusing on patients with challenging solid tumors. The company has raised approximately £25 million to support its clinical-stage development and operates from dedicated facilities at the Oxford Science Park.
Technologies
Keywords
Company Information
- Employees14
- Founded2013
- Total Funding$24636739
Location
1 Robert Robinson Avenue, England, United Kingdom, OX4 4GA
